argenx Invites Shareholders to EGM on Nov 18, 2025
argenx SE, a global leader in immunology, invites shareholders to its Extraordinary General Meeting on Tuesday, November 18, 2025 at 14:00 CET. The event will take place at the offices of Freshfields LLP in Amsterdam.
Shareholders can obtain relevant docs, including the formal notice of convocation, from the argenx website or by emailing [email protected]. The meeting's agenda and ancillary docs are also available for inspection on the argenx website and at their offices.
argenx encourages shareholders to use the voting by (electronic) proxy option. The company has proposed the adoption of a revised remuneration policy during the zoom meeting. argenx, committed to improving lives of people with severe autoimmune diseases, is commercializing the first approved neonatal Fc receptor (FcRn) blocker and evaluating its potential in multiple serious autoimmune diseases.
Shareholders and other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders of argenx SE. The meeting will discuss and vote on the proposed revised remuneration policy, among other items.
Read also:
- Orioles' 2025 Turnaround Powered by Late-Season Pitching Acquisitions
- The Cost of Speech is Zero, True Strength Lies in Unity
- Beginning a Food Truck Venture: Crucial Stages to Achieve Profitability
- Aiming to simplify the move towards cleaner automobiles, the newly established ministry plans to take direct action with Pannier-Runacher, Létard, and Vautrin at the helm.
